BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis, biological evaluation, and docking studies of some novel chalcones as selective COX-2 inhibitors. 2021

Betül Kaya Çavuşoğlu, and Begüm N Sağlık, and Ulviye Acar Çevik, and Derya Osmaniye, and Serkan Levent, and Yusuf Özkay, and Zafer A Kaplancıklı
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Zonguldak Bulent Ecevit University, Zonguldak, Turkey.

A new series of chalcones (1-9) possessing an SO2 CH3 COX-2 pharmacophore at the para position of the C-1 phenyl ring was synthesized via the Claisen-Schmidt condensation reaction and examined for their inhibition potential against cyclooxygenase (COX) enzymes. Their structures were elucidated by infrared, 1 H NMR (nuclear magnetic resonance), 13 C NMR, and high-resolution mass spectroscopic methods. Enzyme inhibition studies revealed that most of the compounds showed a moderate-to-strong inhibitory activity (IC50  = 0.18-0.34 μM) against the COX-2 enzyme as compared with celecoxib (IC50  = 0.12 μM), ibuprofen (IC50  = 5.33 μM), and nimesulide (IC50  = 1.68 μM). Among these compounds, 1-[4-(methylsulfonyl)phenyl]-3-(2,3-dichlorophenyl)prop-2-en-1-one (5), 1-[4-(methylsulfonyl)phenyl]-3-(2,4-dichlorophenyl)prop-2-en-1-one (6), and 1-[4-(methylsulfonyl)phenyl]-3-(2-chloro-6-fluorophenyl)prop-2-en-1-one (8) became prominent with IC50 values of 0.21, 0.19, and 0.18 μM, respectively. According to molecular docking studies of the most effective compounds, it was found that the compounds interact with amino acids that are important in COX-2 selectivity, such as Arg499 and Phe504.

UI MeSH Term Description Entries
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D047188 Chalcones Derivatives of CHALCONE that are important intermediates in the formation of FLAVONOIDS with anti-fungal, anti-bacterial, anti-inflammatory, and anti-tumor properties. 1,3-Diphenyl-propanediones,1,3-Diphenyl-propenones,1,3-Diphenylpropanediones,1,3-Diphenylpropenones,Chalconoids,1,3 Diphenyl propanediones,1,3 Diphenyl propenones,1,3 Diphenylpropanediones,1,3 Diphenylpropenones
D051546 Cyclooxygenase 2 An inducibly-expressed subtype of prostaglandin-endoperoxide synthase. It plays an important role in many cellular processes and INFLAMMATION. It is the target of COX2 INHIBITORS. COX-2 Prostaglandin Synthase,Cyclo-Oxygenase II,Cyclooxygenase-2,PGHS-2,PTGS2,Prostaglandin H Synthase-2,COX 2 Prostaglandin Synthase,Cyclo Oxygenase II,Prostaglandin H Synthase 2,Prostaglandin Synthase, COX-2,Synthase, COX-2 Prostaglandin
D052246 Cyclooxygenase 2 Inhibitors A subclass of cyclooxygenase inhibitors with specificity for CYCLOOXYGENASE-2. COX-2 Inhibitor,COX2 Inhibitor,Coxib,Cyclooxygenase 2 Inhibitor,Cyclooxygenase-2 Inhibitor,COX-2 Inhibitors,COX2 Inhibitors,Coxibs,Cyclooxygenase-2 Inhibitors,2 Inhibitor, Cyclooxygenase,COX 2 Inhibitor,COX 2 Inhibitors,Inhibitor, COX-2,Inhibitor, COX2,Inhibitor, Cyclooxygenase 2,Inhibitor, Cyclooxygenase-2,Inhibitors, COX-2,Inhibitors, COX2,Inhibitors, Cyclooxygenase 2,Inhibitors, Cyclooxygenase-2
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking

Related Publications

Betül Kaya Çavuşoğlu, and Begüm N Sağlık, and Ulviye Acar Çevik, and Derya Osmaniye, and Serkan Levent, and Yusuf Özkay, and Zafer A Kaplancıklı
Synthesis, biological evaluation, and docking studies of novel heterocyclic diaryl compounds as selective COX-2 inhibitors.
September 2010, Bioorganic & medicinal chemistry,
Betül Kaya Çavuşoğlu, and Begüm N Sağlık, and Ulviye Acar Çevik, and Derya Osmaniye, and Serkan Levent, and Yusuf Özkay, and Zafer A Kaplancıklı
Sulfonilamidothiopyrimidone and thiopyrimidone derivatives as selective COX-2 inhibitors: synthesis, biological evaluation, and docking studies.
November 2012, European journal of medicinal chemistry,
Betül Kaya Çavuşoğlu, and Begüm N Sağlık, and Ulviye Acar Çevik, and Derya Osmaniye, and Serkan Levent, and Yusuf Özkay, and Zafer A Kaplancıklı
Design, Synthesis and Biological Evaluation of Novel Peptide-Like Analogues as Selective COX-2 Inhibitors.
January 2018, Iranian journal of pharmaceutical research : IJPR,
Betül Kaya Çavuşoğlu, and Begüm N Sağlık, and Ulviye Acar Çevik, and Derya Osmaniye, and Serkan Levent, and Yusuf Özkay, and Zafer A Kaplancıklı
Design, synthesis, molecular docking studies and biological evaluation of thiazole carboxamide derivatives as COX inhibitors.
March 2023, BMC chemistry,
Betül Kaya Çavuşoğlu, and Begüm N Sağlık, and Ulviye Acar Çevik, and Derya Osmaniye, and Serkan Levent, and Yusuf Özkay, and Zafer A Kaplancıklı
Design, synthesis, and biological evaluation of substituted hydrazone and pyrazole derivatives as selective COX-2 inhibitors: Molecular docking study.
June 2011, Bioorganic & medicinal chemistry,
Betül Kaya Çavuşoğlu, and Begüm N Sağlık, and Ulviye Acar Çevik, and Derya Osmaniye, and Serkan Levent, and Yusuf Özkay, and Zafer A Kaplancıklı
Novel 2-phenyl-4,5,6,7-tetrahydro[b]benzothiophene analogues as selective COX-2 inhibitors: Design, synthesis, anti-inflammatory evaluation, and molecular docking studies.
April 2017, Bioorganic & medicinal chemistry letters,
Betül Kaya Çavuşoğlu, and Begüm N Sağlık, and Ulviye Acar Çevik, and Derya Osmaniye, and Serkan Levent, and Yusuf Özkay, and Zafer A Kaplancıklı
Design, Synthesis, and Biological Evaluation of New Peptide Analogues as Selective COX-2 Inhibitors.
October 2017, Archiv der Pharmazie,
Betül Kaya Çavuşoğlu, and Begüm N Sağlık, and Ulviye Acar Çevik, and Derya Osmaniye, and Serkan Levent, and Yusuf Özkay, and Zafer A Kaplancıklı
Chalcones bearing nitrogen-containing heterocyclics as multi-targeted inhibitors: Design, synthesis, biological evaluation and molecular docking studies.
July 2023, Journal of molecular recognition : JMR,
Betül Kaya Çavuşoğlu, and Begüm N Sağlık, and Ulviye Acar Çevik, and Derya Osmaniye, and Serkan Levent, and Yusuf Özkay, and Zafer A Kaplancıklı
New paracetamol hybrids as anticancer and COX-2 inhibitors: Synthesis, biological evaluation and docking studies.
January 2024, Archiv der Pharmazie,
Betül Kaya Çavuşoğlu, and Begüm N Sağlık, and Ulviye Acar Çevik, and Derya Osmaniye, and Serkan Levent, and Yusuf Özkay, and Zafer A Kaplancıklı
Design and Synthesis of Imidazopyrazolopyridines as Novel Selective COX-2 Inhibitors.
August 2015, Molecules (Basel, Switzerland),
Copied contents to your clipboard!